A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV

Bethany Young Holt, Laura Dellplain, Mitchell D Creinin, Kevin J. Peine, Joseph Romano, Anke Hemmerling

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Multipurpose prevention technologies (MPTs) are an innovative class of products that deliver varied combinations of human immunodeficiency virus (HIV) prevention, other sexually transmitted infection (STI) prevention, and contraception. Combining separate strategies for different indications into singular prevention products can reduce the stigma around HIV and STI prevention, improve acceptability of and adherence to more convenient products, and be more cost-effective by addressing overlapping risks. Methods: This article outlines a strategic action framework developed as an outcome of a series of expert meetings held between 2014 and 2016. The meetings focused on identifying opportunities and challenges for MPTs that combine hormonal contraception (HC) with antiretroviral drugs into single products. The framework aims to present an actionable strategy, by addressing key research gaps and outlining the key areas for progress, to guide current and future HC MPT development. Results: We identified eight primary action areas for the development of impactful HC MPTs, and includes aspects from epidemiology, pharmacology, clinical trial design, regulatory requirements, manufacturing and commercialisation, behavioural science, and investment needs for research and development. Conclusion: Overall, the challenges involved with reconciling the critical social-behavioural context that will drive MPT product use and uptake with the complexities of research and development and regulatory approval are of paramount importance. To realise the potential of MPTs given their complexity and finite resources, researchers in the MPT field must be strategic about the way forward; increased support among policy-makers, advocates, funders and the pharmaceutical industry is critical.

Original languageEnglish (US)
JournalEuropean Journal of Contraception and Reproductive Health Care
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Contraceptive Agents
HIV
Hormones
Technology
Contraception
Pregnancy
Pharmaceutical Preparations
Sexually Transmitted Diseases
Research
Behavioral Sciences
Drug Industry
Administrative Personnel
Epidemiology
Research Personnel
Clinical Trials
Pharmacology
Costs and Cost Analysis

Keywords

  • Action framework
  • contraception
  • HIV
  • MPTs
  • multipurpose prevention technologies
  • prevention

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Pharmacology (medical)

Cite this

A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. / Young Holt, Bethany; Dellplain, Laura; Creinin, Mitchell D; Peine, Kevin J.; Romano, Joseph; Hemmerling, Anke.

In: European Journal of Contraception and Reproductive Health Care, 01.01.2018.

Research output: Contribution to journalArticle

@article{44092ffba6374427b6d03d32f9e6fc4d,
title = "A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV",
abstract = "Objective: Multipurpose prevention technologies (MPTs) are an innovative class of products that deliver varied combinations of human immunodeficiency virus (HIV) prevention, other sexually transmitted infection (STI) prevention, and contraception. Combining separate strategies for different indications into singular prevention products can reduce the stigma around HIV and STI prevention, improve acceptability of and adherence to more convenient products, and be more cost-effective by addressing overlapping risks. Methods: This article outlines a strategic action framework developed as an outcome of a series of expert meetings held between 2014 and 2016. The meetings focused on identifying opportunities and challenges for MPTs that combine hormonal contraception (HC) with antiretroviral drugs into single products. The framework aims to present an actionable strategy, by addressing key research gaps and outlining the key areas for progress, to guide current and future HC MPT development. Results: We identified eight primary action areas for the development of impactful HC MPTs, and includes aspects from epidemiology, pharmacology, clinical trial design, regulatory requirements, manufacturing and commercialisation, behavioural science, and investment needs for research and development. Conclusion: Overall, the challenges involved with reconciling the critical social-behavioural context that will drive MPT product use and uptake with the complexities of research and development and regulatory approval are of paramount importance. To realise the potential of MPTs given their complexity and finite resources, researchers in the MPT field must be strategic about the way forward; increased support among policy-makers, advocates, funders and the pharmaceutical industry is critical.",
keywords = "Action framework, contraception, HIV, MPTs, multipurpose prevention technologies, prevention",
author = "{Young Holt}, Bethany and Laura Dellplain and Creinin, {Mitchell D} and Peine, {Kevin J.} and Joseph Romano and Anke Hemmerling",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/13625187.2018.1508650",
language = "English (US)",
journal = "European Journal of Contraception and Reproductive Health Care",
issn = "1362-5187",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV

AU - Young Holt, Bethany

AU - Dellplain, Laura

AU - Creinin, Mitchell D

AU - Peine, Kevin J.

AU - Romano, Joseph

AU - Hemmerling, Anke

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Multipurpose prevention technologies (MPTs) are an innovative class of products that deliver varied combinations of human immunodeficiency virus (HIV) prevention, other sexually transmitted infection (STI) prevention, and contraception. Combining separate strategies for different indications into singular prevention products can reduce the stigma around HIV and STI prevention, improve acceptability of and adherence to more convenient products, and be more cost-effective by addressing overlapping risks. Methods: This article outlines a strategic action framework developed as an outcome of a series of expert meetings held between 2014 and 2016. The meetings focused on identifying opportunities and challenges for MPTs that combine hormonal contraception (HC) with antiretroviral drugs into single products. The framework aims to present an actionable strategy, by addressing key research gaps and outlining the key areas for progress, to guide current and future HC MPT development. Results: We identified eight primary action areas for the development of impactful HC MPTs, and includes aspects from epidemiology, pharmacology, clinical trial design, regulatory requirements, manufacturing and commercialisation, behavioural science, and investment needs for research and development. Conclusion: Overall, the challenges involved with reconciling the critical social-behavioural context that will drive MPT product use and uptake with the complexities of research and development and regulatory approval are of paramount importance. To realise the potential of MPTs given their complexity and finite resources, researchers in the MPT field must be strategic about the way forward; increased support among policy-makers, advocates, funders and the pharmaceutical industry is critical.

AB - Objective: Multipurpose prevention technologies (MPTs) are an innovative class of products that deliver varied combinations of human immunodeficiency virus (HIV) prevention, other sexually transmitted infection (STI) prevention, and contraception. Combining separate strategies for different indications into singular prevention products can reduce the stigma around HIV and STI prevention, improve acceptability of and adherence to more convenient products, and be more cost-effective by addressing overlapping risks. Methods: This article outlines a strategic action framework developed as an outcome of a series of expert meetings held between 2014 and 2016. The meetings focused on identifying opportunities and challenges for MPTs that combine hormonal contraception (HC) with antiretroviral drugs into single products. The framework aims to present an actionable strategy, by addressing key research gaps and outlining the key areas for progress, to guide current and future HC MPT development. Results: We identified eight primary action areas for the development of impactful HC MPTs, and includes aspects from epidemiology, pharmacology, clinical trial design, regulatory requirements, manufacturing and commercialisation, behavioural science, and investment needs for research and development. Conclusion: Overall, the challenges involved with reconciling the critical social-behavioural context that will drive MPT product use and uptake with the complexities of research and development and regulatory approval are of paramount importance. To realise the potential of MPTs given their complexity and finite resources, researchers in the MPT field must be strategic about the way forward; increased support among policy-makers, advocates, funders and the pharmaceutical industry is critical.

KW - Action framework

KW - contraception

KW - HIV

KW - MPTs

KW - multipurpose prevention technologies

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=85053772693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053772693&partnerID=8YFLogxK

U2 - 10.1080/13625187.2018.1508650

DO - 10.1080/13625187.2018.1508650

M3 - Article

C2 - 30247084

AN - SCOPUS:85053772693

JO - European Journal of Contraception and Reproductive Health Care

JF - European Journal of Contraception and Reproductive Health Care

SN - 1362-5187

ER -